r Human TFPI_2 domain 1
- Known as:
- r Human TFPI_2 domain 1
- Catalog number:
- RF007-1
- Product Quantity:
- 1 mg
- Category:
- -
- Supplier:
- Argen
- Gene target:
- Human TFPI_2 domain 1
Related genes to: r Human TFPI_2 domain 1
- Gene:
- TFPI2 NIH gene
- Name:
- tissue factor pathway inhibitor 2
- Previous symbol:
- -
- Synonyms:
- PP5, TFPI-2, REF1
- Chromosome:
- 7q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-07-14
- Date modifiied:
- 2016-10-05
Related products to: r Human TFPI_2 domain 1
Related articles to: r Human TFPI_2 domain 1
- Diabetic nephropathy (DN) represents the leading cause of end-stage renal disease; however, its molecular mechanisms remain incompletely understood. This study aims to elucidate the specific roles and regulatory mechanisms of Tissue factor pathway inhibitor 2 (TFPI2) and forkhead box O4 (FOXO4) in DN. - Source: PubMed
Publication date: 2026/08/20
Mu LiqinZhao YuLi YangGao WeiWang Jing - Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor existing in two isoforms, TFPI-1 and TFPI-2. Peptides derived from the TFPI C-terminus exhibit potent antimicrobial activity. In this study, a TFPI-1 homolog from Sebastes schlegelii (SsTFPI-1) was identified, and its sequence characteristics, immune response profile, and the antimicrobial activity of its C-terminal peptide TS20 were systematically characterized. The open reading frame of SsTFPI-1 is 867 bp in length, encoding 288 amino acids that comprise a signal peptide, three Kunitz domains, and a low-complexity region. SsTFPI-1 was ubiquitously expressed across all examined tissues, with the highest expression in blood, and its transcript levels were significantly upregulated in the spleen or head kidney following stimulation with Listonella anguillarum, Edwardsiella piscicida, or poly(I:C). Subcellular localization revealed that SsTFPI-1 predominantly localizes in the cytoplasm of EPC cells, and its C-terminus undergoes endogenous cleavage. Antimicrobial assays demonstrated that TS20 exerts pronounced antibacterial activity against Micrococcus luteus with favorable thermal stability. Mechanistically, TS20 disrupts the bacterial cell membrane, enters the cells, binds to DNA, and progressively degrades it. Furthermore, TS20 significantly inhibits SVCV infection in EPC cells by targeting both viral particles and host cells, thereby reducing viral adhesion and entry, while simultaneously downregulating the expression of type I interferon (IFN-I) related genes. In vivo experiments confirmed that TS20 significantly reduced viral loads of SVCV and RBIV-C1 in common carp and turbot, respectively. Collectively, these findings elucidate the immunological role of SsTFPI-1 in S. schlegelii and underscore the potential of TS20 as a promising antimicrobial agent. - Source: PubMed
Publication date: 2026/08/12
Zhu Zhi-ShuChen Zi-YueWang Guang-HuaJing HaoYang KaiSun NuoDu Yi-LinWang Zi-QiZhang Min - Type 1 diabetes (T1D) is an autoimmune disease characterized by progressive β-cell destruction, yet current risk stratification tools, which rely mainly on genetic susceptibility and autoantibody profiles, remain insufficient for accurately predicting disease progression. We aimed to characterize macrophage-related inflammatory transcriptional activity in T1D and to develop peripheral blood-based biomarkers for diagnosis and risk stratification. - Source: PubMed
Publication date: 2026/06/26
Chen YangZhou YiwenLi ShuangChen YuluLiu JingfeiYang ChunZhao HangSu ZhangyaoBian LinglingChen ShuangShen MinQin YaoChen HengXu XinyuShi YunZhang MeiYang TaoGu Yong - Tissue factor pathway inhibitor-2 (TFPI2) is a Kunitz-type serine protease inhibitor and a highly specific biomarker for gynecologic clear cell carcinomas, particularly ovarian clear cell carcinoma (CCC). This review summarizes current evidence on its roles in gynecologic malignancies, focusing on clear cell histology. A structured PubMed search was performed. English-language original articles and reviews addressing the diagnostic, prognostic, and functional roles of TFPI2 were included. Although TFPI2 is commonly silenced as a tumor suppressor in many cancers, it is consistently overexpressed in Müllerian clear cell carcinomas. Clinically, circulating TFPI2 shows high specificity for ovarian CCC, distinguishing it from other ovarian tumors and benign conditions. Its combination with cancer antigen 125 improves diagnostic sensitivity, including in early-stage disease. TFPI2 is selectively expressed in tumor cells, supporting its role as a histology-specific marker across the ovary, endometrium, and cervix. Functionally, TFPI2 may contribute to CCC biology by suppressing cell adhesion and promoting a floating dissemination phenotype. Elevated circulating TFPI2 is associated with poor outcomes in ovarian and endometrial cancers and may reflect coagulation abnormalities. It is also linked to venous thromboembolism and may improve risk stratification when combined with D-dimer. TFPI2 is a unique biomarker with diagnostic, prognostic, and biological significance, with potential applications in precision diagnostics, monitoring, and thrombosis risk assessment. - Source: PubMed
Kawaguchi RyujiMiyagi EtsukoTomoka MaehanaYamada YukiKobayashi HiroshiKimura Fuminori - Immune-mediated killing triggers dynamic transcriptional adaptations in tumor cells that can reciprocally regulate the cytolytic process. Unraveling such feedback mechanisms is crucial for advancing cancer immunotherapy. Here, we identified tissue factor pathway inhibitor 2 (TFPI2) as a central node in natural killer (NK)-glioblastoma cross talk. Using transcriptomic and functional approaches, we demonstrated that NK cell attack induces TFPI2 expression in glioblastoma cells via IL1β- and TNFα-driven activation of NFκB signaling. TFPI2 not only restrains tumor proliferation by suppressing the POU2F2-CCND1 axis but also enhances NK cytotoxicity through two complementary mechanisms: It supports optimal ICAM1 expression to promote NK-tumor adhesion, and it selectively represses the immune checkpoint molecule SIGLEC15, restoring NK cell effector function. In vivo, loss of TFPI2 accelerates glioblastoma progression and abrogates the efficacy of adoptive NK cell therapy in a context-dependent manner; the functionality is likely restricted to tumors retaining the capacity for TFPI2 induction upon inflammatory stimuli. Our findings identified the TFPI2-ICAM1 and TFPI2-SIGLEC15 axes as conditional regulators of immune-tumor adhesion and checkpoint control, supporting TFPI2 as a candidate therapeutic target for a subset of glioblastomas amenable to inflammatory reprogramming. - Source: PubMed
Publication date: 2026/06/18
Zheng DongpengLi FengqiZhang ZhuangDong YunyiZhang XuebinLi XuerenYang JingyuePeng ShouchunChen BudongSun ShupengLiu ZichuanMu Xin